{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T23:47:05Z","timestamp":1783727225135,"version":"3.55.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T00:00:00Z","timestamp":1701734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The incidence of anaphylaxis after receipt of yellow fever (YF) vaccine is highly variable based upon previously published reports. Anaphylaxis after receiving the YF vaccine has been reported to range from 0 up to 22 per 1\u2009000\u2009000 doses. Our clinical experience suggested increased incidence, which prompted our investigation. We sought to evaluate the current incidence rate of anaphylaxis after receipt of the 17D-204 strain YF-VAX\u00ae brand reported in the US.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed a retrospective review of the Vaccine Adverse Event Reporting System (VAERS) reports of anaphylaxis after receiving the YF-VAX vaccine occurring between 1 October 1999 and 30 September 2018. We utilized the Brighton Collaboration Case Definition and inclusion determination was made by a board-certified allergist. We also obtained the total number of YF-VAX doses distributed across the US during this same time-period and then calculated an updated incidence rate of YF-VAX vaccine-associated anaphylaxis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We identified 132 potential cases of possible or probable anaphylaxis. Of these, 111 met inclusion criteria: level 1 (n\u2009=\u200951), level 2 (n\u2009=\u200959) and level 3 (n\u2009=\u20091). The manufacturer reported a total distribution of 7 624 160 doses of YF-VAX from 1 October 1999 to 30 September 2018. The calculated incidence rate of YF-VAX vaccine-associated anaphylaxis is estimated at 14.6 events per 1\u2009000\u2009000 doses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We conclude the estimated rate of anaphylaxis per VAERS reports is 14.6 events per 1\u2009000\u2009000 doses after YF-VAX vaccination. This is consistent with some previous reports and substantially higher than rates of anaphylaxis after other vaccines.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jtm\/taad154","type":"journal-article","created":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T23:54:53Z","timestamp":1701734093000},"source":"Crossref","is-referenced-by-count":8,"title":["Incidence of anaphylaxis to YF-VAX\u00ae yellow fever vaccination: a retrospective evaluation of vaccine adverse event reports 1999\u20132018"],"prefix":"10.1093","volume":"31","author":[{"given":"Bruce M","family":"McClenathan","sequence":"first","affiliation":[{"name":"Immunization Healthcare Division , South Atlantic Region Vaccine Safety Hub, , Fort Liberty, NC , USA"},{"name":"Defense Health Agency , South Atlantic Region Vaccine Safety Hub, , Fort Liberty, NC , USA"},{"name":"Department of Medicine, Womack Army Medical Center , Fort Liberty, NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian N","family":"Taylor","sequence":"additional","affiliation":[{"name":"Campbell University School of Osteopathic Medicine , Lillington, NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie A","family":"Housel","sequence":"additional","affiliation":[{"name":"Immunization Healthcare Division , South Atlantic Region Vaccine Safety Hub, , Fort Liberty, NC , USA"},{"name":"Defense Health Agency , South Atlantic Region Vaccine Safety Hub, , Fort Liberty, NC , USA"},{"name":"Department of Medicine, Womack Army Medical Center , Fort Liberty, NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Ryan","sequence":"additional","affiliation":[{"name":"Immunization Healthcare Division Pacific Region Vaccine Safety Hub, Defense Health Agency , San Diego, CA , USA"},{"name":"Naval Medical Center , San Diego, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,12,5]]},"reference":[{"key":"2024030413222101600_ref1","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1586\/14760584.2013.836320","article-title":"Safety profile of the yellow fever vaccine Stamaril(R): a 17-year review","volume":"12","author":"Cottin","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"2024030413222101600_ref2","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0091-6749(99)70245-9","article-title":"Anaphylaxis from yellow fever vaccine","volume":"103","author":"Kelso","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"2024030413222101600_ref3","doi-asserted-by":"crossref","first-page":"taw045","DOI":"10.1093\/jtm\/taw045","article-title":"Adverse event reports following yellow fever vaccination, 2007-13","volume":"23","author":"Lindsey","year":"2016","journal-title":"J Travel Med"},{"key":"2024030413222101600_ref4","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1016\/j.vaccine.2008.09.009","article-title":"Adverse event reports following yellow fever vaccination","volume":"26","author":"Lindsey","year":"2008","journal-title":"Vaccine"},{"key":"2024030413222101600_ref5","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1016\/j.vaccine.2005.01.089","article-title":"Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events","volume":"23","author":"Khromava","year":"2005","journal-title":"Vaccine"},{"key":"2024030413222101600_ref6","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.jaci.2015.07.048","article-title":"Risk of anaphylaxis after vaccination in children and adults","volume":"137","author":"McNeil","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"2024030413222101600_ref7","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.jaci.2018.12.1003","article-title":"Anaphylaxis after vaccination reported to the vaccine adverse event reporting system, 1990-2016","volume":"143","author":"Su","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"2024030413222101600_ref8","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"key":"2024030413222101600_ref9","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1016\/j.vaccine.2007.02.064","article-title":"Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"25","author":"Ruggeberg","year":"2007","journal-title":"Vaccine"},{"key":"2024030413222101600_ref10","doi-asserted-by":"crossref","first-page":"6201","DOI":"10.1016\/j.vaccine.2013.10.050","article-title":"How many published cases of serious adverse events after yellow fever vaccination meet Brighton Collaboration diagnostic criteria?","volume":"31","author":"Thomas","year":"2013","journal-title":"Vaccine"},{"key":"2024030413222101600_ref11","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/B978-0-323-35761-6.00063-8","volume-title":"63 - Yellow Fever Vaccines, in Plotkin's Vaccines","author":"Staples","year":"2018","edition":"7th"},{"key":"2024030413222101600_ref12","first-page":"1","article-title":"Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices \u2014 United States, 2023\u201324 Influenza Season","volume":"72","author":"Grohskopf","year":"2023","journal-title":"Morb Mortal Wkly Rep"},{"key":"2024030413222101600_ref13","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.jaip.2015.03.011","article-title":"Ovalbumin content in the yellow fever vaccine","volume":"3","author":"Smith","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024030413222101600_ref14","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/pai.13125","article-title":"Food and drug allergy, and anaphylaxis in EAACI journals (2018)","volume":"30","author":"Eigenmann","year":"2019","journal-title":"Pediatr Allergy Immunol"},{"key":"2024030413222101600_ref15","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taac070","article-title":"A nationwide prospective cohort study on safety of the 17D-204 yellow fever vaccine during a vaccine shortage in Japan","volume":"30","author":"Miyazato","year":"2023","journal-title":"J Travel Med"},{"key":"2024030413222101600_ref16","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taad037","article-title":"Enhanced safety surveillance of STAMARIL\u00ae yellow fever vaccine provided under the expanded access investigational new drug program in the United States","volume":"30","author":"Rojas","year":"2023","journal-title":"J Travel Med"},{"key":"2024030413222101600_ref17","doi-asserted-by":"crossref","first-page":"7458","DOI":"10.1016\/j.vaccine.2020.09.072","article-title":"The reporting sensitivity of the Vaccine Adverse Event Reporting System (VAERS) for anaphylaxis and for Guillain-Barre syndrome","volume":"38","author":"Miller","year":"2020","journal-title":"Vaccine"},{"key":"2024030413222101600_ref18","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taab126","article-title":"Long-term immunity after a single yellow fever vaccination in travelers vaccinated at 60 years or older: A 10-year follow-up study","volume":"28","author":"Rosenstein","year":"2021","journal-title":"J Travel Med"},{"key":"2024030413222101600_ref19","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taad085","article-title":"Travel vaccines-priorities determined by incidence and impact","volume":"30","author":"Steffen","year":"2023","journal-title":"J Travel Med"},{"key":"2024030413222101600_ref20","article-title":"Yellow fever vaccine safety in immunocompromised individuals: a systematic review and meta-analysis","volume":"30","author":"Ara\u00fajo Lagos","year":"2023","journal-title":"J Travel Med"}],"container-title":["Journal of Travel Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jtm\/advance-article-pdf\/doi\/10.1093\/jtm\/taad154\/54705270\/taad154.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jtm\/article-pdf\/31\/2\/taad154\/56813072\/taad154.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jtm\/article-pdf\/31\/2\/taad154\/56813072\/taad154.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T13:22:36Z","timestamp":1709558556000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jtm\/article\/doi\/10.1093\/jtm\/taad154\/7458946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,5]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,12,5]]},"published-print":{"date-parts":[[2024,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jtm\/taad154","relation":{},"ISSN":["1195-1982","1708-8305"],"issn-type":[{"value":"1195-1982","type":"print"},{"value":"1708-8305","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3]]},"published":{"date-parts":[[2023,12,5]]},"article-number":"taad154"}}